Skip to main content

SARS-CoV-2 Nanogel Sublingual Vaccine

Award type :
Product Development Award
Product type :
Vaccines
Award year :
2020
Project start date :
07 / 09 / 2020
Project end date :
04 / 30 / 2021
Project duration (months) :
10
Development stage :
Preclinical
Target disease :
COVID-19
Region served :
World
Recipient organization / Country of funding recipient organization :
KCAV / Republic of Korea
Collaborator(s) / Country :
SD Biosensor / Republic of Korea
Funding amount(KRW) :
400,000,000

This project by Konkuk Ctc bio Animal Vaccine (KCAV) aims to develop a nanogel adjuvant sublingual vaccine for SARS-CoV-2. Sublingual administration of vaccines can elicit immunity at mucosal sites. The nanogel carrier may have applications in other recombinant viral vaccines.